MSF appreciates EC pharma legislation proposal to improve transparency by industry and the granting of compulsory licenses on medicines in the EU.

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many

For World Immunization Week 2023, MSF calls on Gavi to expand its policy to catch up young children on missed vaccinations.

With affordable generics likely years away, ViiV must make information public on supply of long-acting cabotegravir and global distribution plan to ensure access for people in high HIV burden low- and middle-income countries

2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.

MSF called on governments and donors to speed up access to diagnostic tests, and shorter, safer and more effective treatments, for DR-TB.

MSF response to negotiations on an India-EU free trade agreement (FTA) regarding harmful intellectual property (IP) provisions

MSF statement at the Fourth meeting of the Intergovernmental Negotiating Body (INB) for a World Health Organization instrument on pandemic prevention, preparedness and response.

Gavi's new CEO must prioritise catch-up vaccinations for young children, and more inclusive decision-making.

MSF representatives will speak at the 152nd session of the WHO Executive Board (EB) on a number of topics.

MSF Statement on EB152/13 - Strengthening clinical trials

MSF Statement on EB152/7 - Substandard and falsified medical products

MSF Statement on EB152/5 - Strengthening diagnostics capacity

Ahead of World Neglected Tropical Disease (NTD) Day 30 January, MSF demands improved global response for NTDs, including increased investment.

Ahead of the final hearing on a patent challenge by two TB survivors, MSF urges the Indian Patent Office to reject Johnson & Johnson’s secondary patent application so that other manufacturers may enter the supply chain with more ...

Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of ...

MSF authors describe medical activities for people for snakebite, including the importance of offering antivenom free of charge, though costly for MSF.

The World Health Organization’s Global Tuberculosis Report 2022 highlights that still only one in three people with drug-resistant tuberculosis is getting treatment, and the treatment success rate for those who do receive treatment ...